Prof Paola Ghione speaks to ecancer about the clinical outcomes from ZUMA-5 (axicabtagene ciloleucel) and the international SCHOLAR-5 external control cohort in relapsed/refractory follicular lymphoma (R/R FL). Initially, she talks about the background of the study. Prof Ghione then describes the methodology and key results of the study.

Compared to currently available therapies in r/r FL patients, axi-cel demonstrated a substantial and statistically significant improvement in meaningful clinical endpoints including ORR, PFS, TTNT and OS, highlighting the durable treatment effect of axi-cel.

These findings suggest that axi-cel addresses an important unmet medical need for r/r FL patients. In the end, Prof Ghione discusses the impact these results can have on relapsed/refractory follicular lymphoma.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.